Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC
Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC PR Newswire ATLANTA, Aug. 20, 2026 Neuroscience...
PR Newswire
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain
Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain PR Newswire ATLANTA, Aug. 18...
PR Newswire
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending
Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending PR Newswire ATLANTA, Aug. 4, 2026 Company received $7.5 million in gross proceeds from the initial tranche of...
PR Newswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Alzamend Neuro (NASDAQ:ALZN) stock increased by 12.9% to $1.35 during Tuesday's after-market session. The company's market cap stands at $4.4 million.
Vivos Therapeutics (NASDAQ:VVOS) shares increasedread more...
Benzinga
Insider Buying: Alzamend Neuro (NASDAQ:ALZN) Director Buys 108,388 Shares of Stock
Alzamend Neuro, Inc. (NASDAQ:ALZN - Get Free Report) Director Milton Ault III bought 108,388 shares of the stock in a transaction dated Tuesday, April 14th. The shares were purchased at an average price of $1.00 per share, for a total transaction of $108,388.00. Following the purchase, the director...
MarketBeat
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital
Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 'Lithium in Brain' Study in a Trial Conducted at Massachusetts General Hospital Alzamend Neuro Reports...
PR Newswire
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions
Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001...
PR Newswire
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital
Alzamend Neuro Initiates Phase II Clinical Trial of AL001 'Lithium in Brain' Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital Alzamend Neuro Initiates...
PR Newswire
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Here is how Allogene Therapeutics (ALLO) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
Zacks
Is AIM ImmunoTech (AIM) Stock Outpacing Its Medical Peers This Year?
Here is how AIM ImmunoTech Inc. (AIM) and Alzamend Neuro, Inc. (ALZN) have performed compared to their sector so far this year.
Zacks